Perfluoroctylbromide and hepatosplenic computed tomography: Preliminary clinical study

J. N. Bruneton, M. N. Falewee, C. Balu-Maestro, F. Normand, R. F. Mattrey

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


The preliminary results of perfluoroctylbromide (PFOB) emulsion when used an an intravenous contrast agent for hepatosplenic CT imaging in humans are reported. Ten patients were examined using dosages ranging from 1 to 2 g/kg. There was good clinical and biochemical tolerance. Diagnostic dose for liver enhancement seems to be at least 2 g/kg, whereas 1 g/kg was sufficient for splenic enhancement.

Original languageEnglish (US)
Pages (from-to)S306-S307
JournalInvestigative Radiology
Issue numberSUPPL. 1
StatePublished - Jan 1 1988

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Perfluoroctylbromide and hepatosplenic computed tomography: Preliminary clinical study'. Together they form a unique fingerprint.

Cite this